News

Public · Published

Moderna: Following Phase 3 Interim Analysis of mRNA-1403, Which Did Not Meet Statistical Criteria for Early Success, Co. Does Not Plan to Initiate Additional Cohort This Season >MRNA

Moderna said an interim review of its Phase 3 mRNA-1403 study did not meet the statistical criteria for early success. The company also said it does not plan to start an additional study group this season.

Published:

Updated:

What happened

Moderna said an interim review of its Phase 3 mRNA-1403 study did not meet the statistical criteria for early success. The company also said it does not plan to start an additional study group this season.

Confirmed

Global impact / market context

The result removes the prospect of an additional study group this season and leaves the program without early-success evidence at this review. If this affects development timing, spending on the study could be delayed or redirected, while expectations for future product revenue may shift.

Analyst inference

This is a clinical-development update, not a reported sales or earnings change. Phase 3 is a late-stage human study; an interim analysis is a review before the study ends. The article provides no timeline, financial impact, or explanation of the study’s next steps.

Confirmed

What to watch

  1. Whether Moderna provides further results from the Phase 3 study, including the final analysis, which could clarify whether mRNA-1403 met its study goals. Analyst inference
  2. Whether the company confirms another study group will not start this season and explains any resulting change to the program’s schedule. Analyst inference
  3. Any company update on whether the interim result changes study spending or the timing of future development, neither of which is specified here. Analyst inference

Evidence

  • Original source link unavailable